Phase 2 Clinical Trials

Mid-stage Phase 2 clinical trial results showing efficacy and safety data.

100 UpcomingView Full Calendar

March 202621

Tomorrow

CELG-RIPhase 2

Afimetoran Phase 2 Results Expected

Afimetoran• Systemic Lupus Erythematosus268

Mar 29Estimated

CT.gov

00%

Tomorrow

MRKPhase 2$245.9B

Belzutifan Phase 2 Results Expected

Belzutifan• Renal Cell Carcinoma50

Mar 29Estimated

CT.gov

00%

days

JNGHFPhase 2

SHR-3167 Phase 2 Results Expected

SHR-3167• Type 2 Diabetes275

Mar 30Estimated

CT.gov

00%

days

JNGHFPhase 2

Insulin glargine Phase 2 Results Expected

INS068 injection• Type 2 Diabetes275

Mar 30Estimated

CT.gov

00%

days

IGCPhase 2$26M

IGC-AD1-Active Phase 2 Results Expected

IGC-AD1-Active• Alzheimer Disease164

Mar 30Estimated

CT.gov

00%

days

NVSPhase 2$274.7B

Iptacopan (part 1) Phase 2 Results Expected

Iptacopan (part 1)• Lupus Nephritis240

Mar 30Estimated

CT.gov

00%

days

APLMPhase 2$20M

APL-101 Oral Capsules Phase 2 Results Expected

APL-101 Oral Capsules• Solid Tumors497

Mar 30Estimated

CT.gov

00%

days

PFEPhase 2$142.7B

PF-07104091 monotherapy dose escalation Phase 2 Results Expected

PF-07104091 monotherapy dose escalation• Small Cell Lung Cancer154

Mar 30Estimated

CT.gov

00%

days

NTHIPhase 2$138M

Perillyl alcohol Phase 2 Results Expected

Perillyl alcohol• Glioblastoma Multiforme49

Mar 30Estimated

CT.gov

00%

days

XLOPhase 2$50M

vilastobart (XTX101) Phase 2 Results Expected

vilastobart (XTX101)• Advanced Solid Tumor136

Mar 30Estimated

CT.gov

00%

days

PFEPhase 2$142.7B

Tisotumab Vedotin Phase 2 Results Expected

Tisotumab Vedotin• Cervical Cancer214

Mar 31Estimated

CT.gov

00%

days

ESALYPhase 2

E7389-LF Phase 2 Results Expected

E7389-LF• Solid Neoplasms125

Mar 31Estimated

CT.gov

00%

days

MSCLFPhase 2$188M

SAT-3247 Phase 2 Results Expected

SAT-3247• Duchenne Muscular Dystrophy

Mar 31Estimated

CT.gov

00%

days

PFEPhase 2$142.7B

Fulvestrant Phase 2 Results Expected

fulvestrant• Uterine Neoplasms333

Mar 31Estimated

CT.gov

00%

days

SNYPhase 2$115.3B

Pandemic flu H5 mRNA vaccine Phase 2 Results Expected

Pandemic flu H5 mRNA vaccine• Influenza Immunization276

Mar 31Estimated

CT.gov

00%

days

PFEPhase 2$142.7B

Exemestane Phase 2 Results Expected

exemestane• Breast Neoplasms333

Mar 31Estimated

CT.gov

00%

days

ESALYPhase 2

E7090 Phase 2 Results Expected

E7090• Cholangiocarcinoma63

Mar 31Estimated

CT.gov

00%

days

TAKPhase 2$48.3B

Dazostinag Phase 2 Results Expected

Dazostinag• Solid Neoplasms248

Mar 31Estimated

CT.gov

00%

days

AURAPhase 2$428M

AU-011 Phase 2 Results Expected

AU-011• Eye Cancer24

Mar 31Estimated

CT.gov

00%

days

PFEPhase 2$142.7B

PF-07220060 CDK4 inhibitor Phase 2 Results Expected

PF-07220060 CDK4 inhibitor• Advanced or Metastatic Breast Cancer333

Mar 31Estimated

CT.gov

00%

days

INVAPhase 2$899M

VI-0609 Phase 2 Results Expected

VI-0609• Lymphoma49

Mar 31Estimated

CT.gov

00%

April 202661

JSPRPhase 2$31M

Briquilimab Phase 2 Results Expected

Briquilimab• Chronic Spontaneous Urticaria80

Apr 1Estimated

CT.gov

00%

CRISPhase 2$28M

Emavusertib Phase 2 Results Expected

Emavusertib• Acute Myelogenous Leukemia366

Apr 1Estimated

CT.gov

00%

AMGNPhase 2$167.6B

AMG 193 Phase 2 Results Expected

AMG 193• MTAP-deleted NSCLC53

Apr 1Estimated

CT.gov

00%

AMGNPhase 2$167.6B

IDE397 Phase 2 Results Expected

IDE397• MTAP-null Non-Small-Cell Lung Cancer53

Apr 1Estimated

CT.gov

00%

SNYPhase 2$115.3B

IIV-HD Phase 2 Results Expected

IIV-HD• COVID-19 Immunization

Apr 1Estimated

CT.gov

00%

SNYPhase 2$115.3B

Sarilumab SAR153191 (REGN88) Phase 2 Results Expected

Sarilumab SAR153191 (REGN88)• Juvenile Idiopathic Arthritis51

Apr 1Estimated

CT.gov

00%

ZEALPhase 2

Petrelintide Phase 2 Results Expected

Petrelintide• Obesity221

Apr 2Estimated

CT.gov

00%

BIOPhase 2$6.2B

BAT8008 injection Phase 2 Results Expected

BAT8008 injection• Advanced Solid Tumors112

Apr 3Estimated

CT.gov

00%

SNYPhase 2$115.3B

RIV (recombinant influenza vaccine) Phase 2 Results Expected

RIV (recombinant influenza vaccine)• COVID-19 Immunization980

Apr 3Estimated

CT.gov

00%

MRKPhase 2$245.9B

Frespaciguat Phase 2 Results Expected

Frespaciguat• Pulmonary Hypertension

Apr 7Estimated

CT.gov

00%

PFEPhase 2$142.7B

Cetuximab Phase 2 Results Expected

Cetuximab• Squamous Cell Carcinoma of the Head and Neck (SCCHN)107

Apr 12Estimated

CT.gov

00%

MRNAPhase 2$42.1B

mRNA-1405 Phase 2 Results Expected

mRNA-1405• Norovirus Acute Gastroenteritis1,285

Apr 14Estimated

CT.gov

00%

INCYPhase 2$9.9B

INCAGN02390 Phase 2 Results Expected

INCAGN02390• Melanoma206

Apr 14Estimated

CT.gov

00%

INCYPhase 2$9.9B

retifanlimab Phase 2 Results Expected

Retifanlimab• Metastatic Merkel Cell Carcinoma206

Apr 14Estimated

CT.gov

00%

INCYPhase 2$9.9B

pemigatinib Phase 2 Results Expected

Pemigatinib• Non-Small Cell Lung Cancer (NSCLC)206

Apr 14Estimated

CT.gov

00%

INCYPhase 2$9.9B

epacadostat Phase 2 Results Expected

Epacadostat• Lung Cancer206

Apr 14Estimated

CT.gov

00%

INCYPhase 2$9.9B

INCAGN02385 Phase 2 Results Expected

INCAGN02385• Endometrial Cancer206

Apr 14Estimated

CT.gov

00%

AAPGPhase 2$2.7B

APG-115 Phase 2 Results Expected

APG-115• AML95

Apr 15Estimated

CT.gov

00%

JNGHFPhase 2

HRS-6768 Phase 2 Results Expected

HRS-6768• Advanced Solid Tumors84

Apr 15Estimated

CT.gov

00%

GILDPhase 2$60.0B

Tilpisertib Fosmecarbil Phase 2 Results Expected

Tilpisertib Fosmecarbil• Ulcerative Colitis176

Apr 15Estimated

CT.gov

00%

GILDPhase 2$60.0B

Placebo Phase 2 Results Expected

Seladelpar 10 mg• Primary Biliary Cholangitis176

Apr 15Estimated

CT.gov

00%

AAPGPhase 2$2.7B

Toripalimab Phase 2 Results Expected

Toripalimab• Liposarcoma95

Apr 15Estimated

CT.gov

00%

YMABPhase 2$450M

GM-CSF + Naxitamab Phase 2 Results Expected

GM-CSF + Naxitamab• Neuroblastoma122

Apr 15Estimated

CT.gov

00%

LIFEPhase 2$803M

efzofitimod 450 mg Phase 2 Results Expected

efzofitimod 450 mg• Interstitial Lung Disease25

Apr 15Estimated

CT.gov

00%

LLYPhase 2$769.8B

Bimagrumab Phase 2 Results Expected

Bimagrumab• Obesity240

Apr 15Estimated

CT.gov

00%

ORKAPhase 2$1.7B

ORKA-001 Induction Dose Phase 2 Results Expected

ORKA-001 Induction Dose• Plaque Psoriasis80

Apr 15Estimated

CT.gov

00%

CALCPhase 2$9M

Auxora Phase 2 Results Expected

Auxora• Acute Kidney Injury150

Apr 15Estimated

CT.gov

00%

VMARPhase 2$10M

Atropine Phase 2 Results Expected

Atropine• Myopia, Progressive144

Apr 15Estimated

CT.gov

00%

KPTIPhase 2$96M

Selinexor 60 mg Phase 2 Results Expected

Selinexor 60 mg• Myelofibrosis118

Apr 15Estimated

CT.gov

00%

VTGNPhase 2$24M

Fasedienol Nasal Spray - Fasedienol Nasal Spray Phase 2 Results Expected

Fasedienol Nasal Spray - Fasedienol Nasal Spray• Social Anxiety Disorder60

Apr 15Estimated

CT.gov

00%

VMARPhase 2$10M

SHJ002 Phase 2 Results Expected

SHJ002• Corneal Erosion144

Apr 15Estimated

CT.gov

00%

KYTXPhase 2$345M

Standard lymphodepletion regimen Phase 2 Results Expected

Standard lymphodepletion regimen• Lupus Nephritis25

Apr 15Estimated

CT.gov

00%

AAPGPhase 2$2.7B

APG-2575 Phase 2 Results Expected

APG-2575• T-Prolymphocytic Leukemia40

Apr 15Estimated

CT.gov

00%

KPTIPhase 2$96M

Selinexor 40 mg Phase 2 Results Expected

Selinexor 100 mg• Non-Small Cell Lung Carcinoma (NSCLC)118

Apr 15Estimated

CT.gov

00%

KPTIPhase 2$96M

Ruxolitinib Phase 2 Results Expected

Ruxolitinib• Myelofibrosis118

Apr 15Estimated

CT.gov

00%

ODYYPhase 2$6M

OD-07656 Phase 2 Results Expected

OD-07656• Ulcerative Colitis (UC)57

Apr 15Estimated

CT.gov

00%

LLYPhase 2$769.8B

LY3549492 Phase 2 Results Expected

LY3549492• Obesity275

Apr 15Estimated

CT.gov

00%

SNYPhase 2$115.3B

Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 Phase 2 Results Expected

Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1• Influenza1,162

Apr 16Estimated

CT.gov

00%

REGNPhase 2$113.8B

Carboplatin Phase 2 Results Expected

Carboplatin• Resectable Non-small Cell Lung Cancer195

Apr 17Estimated

CT.gov

00%

LSTAPhase 2$45M

certepetide Phase 2 Results Expected

certepetide• Cholangiocarcinoma67

Apr 18Estimated

CT.gov

00%

MRKPhase 2$245.9B

ATRA Phase 2 Results Expected

ATRA• Melanoma315

Apr 20Estimated

CT.gov

00%

MRKPhase 2$245.9B

Vibostolimab Phase 2 Results Expected

Vibostolimab• Melanoma315

Apr 20Estimated

CT.gov

00%

MRKPhase 2$245.9B

Pembrolizumab/Quavonlimab Phase 2 Results Expected

Pembrolizumab/Quavonlimab• Colorectal Cancer315

Apr 20Estimated

CT.gov

00%

MRKPhase 2$245.9B

pembrolizumab Phase 2 Results Expected

pembrolizumab• Non-small Cell Lung Cancer315

Apr 20Estimated

CT.gov

00%

MRKPhase 2$245.9B

favezelimab/pembrolizumab Phase 2 Results Expected

favezelimab/pembrolizumab• Hodgkin Lymphoma315

Apr 20Estimated

CT.gov

00%

MRKPhase 2$245.9B

lenvatinib Phase 2 Results Expected

Lenvatinib• Non-small Cell Lung Cancer315

Apr 20Estimated

CT.gov

00%

MRKPhase 2$245.9B

Zilovertamab vedotin Phase 2 Results Expected

MK-2140 (zilovertamab vedotin)• Relapsed or Refractory Diffuse Large B-Cell Lymphoma140

Apr 22Estimated

CT.gov

00%

RHHBYPhase 2$344.8B

RO7795081 Phase 2 Results Expected

RO7795081• Obesity or Overweight340

Apr 23Estimated

CT.gov

00%

2mo

HNSPFPhase 2$31.6B

HS-10374 Phase 2 Results Expected

HS-10374• Psoriatic Arthritis160

Apr 28Estimated

CT.gov

00%

2mo

VRNAPhase 2$1.1B

Glycopyrrolate 21.25 mcg Phase 2 Results Expected

Glycopyrrolate 21.25 mcg• Chronic Obstructive Pulmonary Disease480

Apr 29Estimated

CT.gov

00%

2mo

VRNAPhase 2$1.1B

Ensifentrine 3 mg Phase 2 Results Expected

Ensifentrine 3 mg• Chronic Obstructive Pulmonary Disease480

Apr 29Estimated

CT.gov

00%

2mo

VRTXPhase 2$121.8B

Placebo (matched to pregabalin) Phase 2 Results Expected

VX-548• Acute Pain300

Apr 30Estimated

CT.gov

00%

2mo

TTIPFPhase 2$20M

TTI-0102 Phase 2 Results Expected

TTI-0102• MELAS Syndrome12

Apr 30Estimated

CT.gov

00%

2mo

PFEPhase 2$142.7B

Samuraciclib Phase 2 Results Expected

Samuraciclib• Breast Cancer11

Apr 30Estimated

CT.gov

00%

2mo

PFEPhase 2$142.7B

vepdegestrant Phase 2 Results Expected

vepdegestrant• Breast Cancer11

Apr 30Estimated

CT.gov

00%

2mo

GSKPhase 2$99.3B

Zanamivir Phase 2 Results Expected

Zanamivir• Influenza, Human12

Apr 30Estimated

CT.gov

00%

2mo

CNTAPhase 2$3.7B

ORX750 Phase 2 Results Expected

ORX750• Narcolepsy Type 190

Apr 30Estimated

CT.gov

00%

2mo

DNLIPhase 2$1.9B

BIIB122 225 mg Phase 2 Results Expected

BIIB122 225 mg• Parkinson Disease50

Apr 30Estimated

CT.gov

00%

2mo

MRKPhase 2$245.9B

Tulisokibart Phase 2 Results Expected

Tulisokibart• Hidradenitis Suppurativa154

Apr 30Estimated

CT.gov

00%

2mo

ANROPhase 2$590M

DR30206 Phase 2 Results Expected

DR30206• Gastrointestinal Cancer186

Apr 30Estimated

CT.gov

00%

2mo

TLSAPhase 2$150M

Foralumab TZLS-401 100 µg Phase 2 Results Expected

Foralumab TZLS-401 100 µg• Non-Active Secondary Progressive Multiple Sclerosis55

Apr 30Estimated

CT.gov

00%

May 202618

2mo

AZNCFPhase 2$290.6B

AZD7798 Phase 2 Results Expected

AZD7798• Moderate to Severe Crohn's Disease120

May 1Estimated

CT.gov

00%

2mo

BAVA.COPhase 2$15.6B

MVA-BN Phase 2 Results Expected

MVA-BN• Monkeypox (Mpox)460

May 1Estimated

CT.gov

00%

2mo

CELZPhase 2$7M

CELZ-201-DDT Phase 2 Results Expected

CELZ-201-DDT• Chronic Low-back Pain45

May 1Estimated

CT.gov

00%

2mo

AZNPhase 2$291.4B

AZD7798 Phase 2 Results Expected

AZD7798• Crohn's Disease30

May 4Estimated

CT.gov

00%

2mo

RCKTPhase 2$1.4B

RP-L102 Phase 2 Results Expected

RP-L102• Fanconi Anemia Complementation Group A5

May 5Estimated

CT.gov

00%

2mo

AZNPhase 2$291.4B

AZD3470 Phase 2 Results Expected

AZD3470• Lymphoma110

May 8Estimated

CT.gov

00%

2mo

INCYPhase 2$9.9B

INCB177054 Phase 2 Results Expected

INCB177054• Solid Tumors9

May 8Estimated

CT.gov

00%

2mo

CLCSPhase 2$33M

mesenchymal stem cells Phase 2 Results Expected

mesenchymal stem cells• Lung Injury80

May 10Estimated

CT.gov

00%

2mo

NVSPhase 2$274.7B

CPK850 Phase 2 Results Expected

CPK850• Retinitis Pigmentosa12

May 11Estimated

CT.gov

00%

2mo

ALPMYPhase 2$25.6B

enfortumab vedotin (EV) Phase 2 Results Expected

enfortumab vedotin (EV)• Carcinoma, Transitional Cell348

May 11Estimated

CT.gov

00%

2mo

HCMPhase 2$2.3B

HMPL-760 planned dose 1 Phase 2 Results Expected

HMPL-760 planned dose 1• Relapsed/Refractory Diffuse Large B-Cell Lymphoma61

May 12Estimated

CT.gov

00%

2mo

REGNPhase 2$113.8B

Placebo Phase 2 Results Expected

Dupilumab• Atopic Dermatitis (AD)180

May 13Estimated

CT.gov

00%

2mo

REGNPhase 2$113.8B

Cemiplimab Phase 2 Results Expected

cemiplimab• Advanced Cutaneous Squamous Cell Carcinoma180

May 13Estimated

CT.gov

00%

2mo

REGNPhase 2$113.8B

Pemetrexed Phase 2 Results Expected

Pemetrexed• Non-small Cell Lung Cancer180

May 13Estimated

CT.gov

00%

2mo

REGNPhase 2$113.8B

Fianlimab Phase 2 Results Expected

Fianlimab• Melanoma180

May 13Estimated

CT.gov

00%

2mo

RHHBYPhase 2$344.8B

Entrectinib Phase 2 Results Expected

Entrectinib• Solid Tumors534

May 14Estimated

CT.gov

00%

2mo

BIIBPhase 2$33.7B

BIIB080 Phase 2 Results Expected

BIIB080• Alzheimer Disease416

BTDFTOrphan

May 14Estimated

CT.gov

00%

2mo

GILDPhase 2$60.0B

Lenacapavir Injection Phase 2 Results Expected

Lenacapavir Injection• Pre-Exposure Prophylaxis of HIV Infection268

May 15Estimated

CT.gov

00%

Get Phase 2 Clinical Trials Alerts

About Phase 2 Clinical Trials

Mid-stage Phase 2 clinical trial results showing efficacy and safety data.